Tag: stageIV

News

10/07/20

Differences in HER2 expression between tumors affects outcomes

05/13/12

A story of long-term stage IV HER2+ breast cancer survival

12/02/11

Knowing receptor status of metastases improves treatment decisions

11/14/11

Cancer marker CA15-3 can sometimes predict metastasis

11/09/11

Curcumin reduces breast cancer resistance to Adriamycin

Studies

• The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype Cite
  Ziegler P, Hartkopf AD, Wallwiener M, Häberle L, Kolberg H, Hadji P, et al. The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype. BMC Cancer. Springer Science and Business Media LLC; 2024; 24 10.1186/s12885-024-13038-3
• Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer Cite
  Zimmer P, Esser T, Lueftner D, Schuetz F, Baumann FT, Rody A, et al. Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer. BMC Medicine. Springer Science and Business Media LLC; 2024; 22 10.1186/s12916-024-03671-x
• Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease Cite
  Dowling GP, Keelan S, Cosgrove NS, Daly GR, Giblin K, Toomey S, et al. Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07431-6
• Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypes Cite
  Kadamkulam Syriac A, Nandu NS, Clark A, Tavallai M, Jin DX, Sokol E, et al. Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypes. Breast Cancer Research. Springer Science and Business Media LLC; 2024; 26 10.1186/s13058-024-01872-z
• Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy Cite
  Jia L, Peng J, Sun N, Chen H, Liu Z, Zhao W, et al. Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy. BMC Cancer. Springer Science and Business Media LLC; 2024; 24 10.1186/s12885-024-12621-y
• A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes Cite
  Campbell TM, Campbell EK, Culakova E, Blanchard LM, Wixom N, Guido JJ, et al. A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 205:257-266 10.1007/s10549-024-07266-1
• Association between diabetes and subsequent malignancy risk among older breast cancer survivors Cite
  Hardell KNL, Schonfeld SJ, Ramin C, Vo JB, Morton LM. Association between diabetes and subsequent malignancy risk among older breast cancer survivors. JNCI Cancer Spectrum. Oxford University Press (OUP); 2024; 10.1093/jncics/pkae036
• Discordance of HER2-low Status between Breast Primary and Distant Metastases with Clinical-pathological Correlation Cite
  Yang E, D’Alfonso T, Morrow M, Brogi E, Wen H. Discordance of HER2-low Status between Breast Primary and Distant Metastases with Clinical-pathological Correlation. Research Square Platform LLC; 2024; 10.21203/rs.3.rs-4284023/v1
• Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort Cite
  Pla H, Felip E, Obadia V, Pernas S, Viñas G, Margelí M, et al. Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort. Clinical and Translational Oncology. Springer Science and Business Media LLC; 2024; 10.1007/s12094-024-03399-3
• Survival Analysis of Male Patients with Brain Metastases at Initial Breast Cancer Diagnosis over the Last Decade Cite
  Avila J, Leone J, Vallejo CT, Leone JP. Survival Analysis of Male Patients with Brain Metastases at Initial Breast Cancer Diagnosis over the Last Decade. Medical Sciences. MDPI AG; 2024; 12:15 10.3390/medsci12010015
• Metastatic Profiles and Survival Differences Between Infiltrating Ductal Carcinoma and Infiltrating Lobular Carcinoma in Invasive Breast Cancer Cite
  CAVALLER L, GOUPILLE C, ARBION F, VILDE A, BODY G, OULDAMER L. Metastatic Profiles and Survival Differences Between Infiltrating Ductal Carcinoma and Infiltrating Lobular Carcinoma in Invasive Breast Cancer. Journal of Gynecology Obstetrics and Human Reproduction. Elsevier BV; 2024;:102740 10.1016/j.jogoh.2024.102740
• Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience Cite
  Piedra-Delgado L, Chambergo-Michilot D, Morante Z, Fairen C, Jerves-Coello F, Luque-Benavides R, et al. Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience. PLOS ONE. Public Library of Science (PLoS); 2024; 19:e0293833 10.1371/journal.pone.0293833
• Effectiveness of Nigella sativa Addition against TNF-Alpha in Stage III and IV Breast Cancer Undergoing Doxorubicin and Cyclophosphamide Chemotherapy at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia Cite
  Friyoga Syahril , Wirdah A, Nur Qodir , Irfanuddin , Irsan Saleh , Yenny Dian Andayani , et al. Effectiveness of Nigella sativa Addition against TNF-Alpha in Stage III and IV Breast Cancer Undergoing Doxorubicin and Cyclophosphamide Chemotherapy at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia. Bioscientia Medicina : Journal of Biomedicine and Translational Research. Hanif Medisiana Publisher; 2023; 8:4009-4014 10.37275/bsm.v8i2.924
• First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort Cite
  Galvin A, Courtinard C, Bouteiller F, Gourgou S, Dalenc F, Jacot W, et al. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort. European Journal of Cancer. Elsevier BV; 2024; 196:113422 10.1016/j.ejca.2023.113422
• Mechanism of synergistic inhibitory effect of benzyl isothiocyanate and zoledronic acid combination on breast cancer induction of osteoclast differentiation Cite
  Hahm E, Kim S, Pore SK, Mathan SV, Singh RP, Singh SV. Mechanism of synergistic inhibitory effect of benzyl isothiocyanate and zoledronic acid combination on breast cancer induction of osteoclast differentiation. Molecular Carcinogenesis. Wiley; 2023; 10.1002/mc.23653
• Frequency of genetic alterations differs in advanced breast cancer between metastatic sites Cite
  Grote I, Poppe A, Lehmann U, Christgen M, Kreipe H, Bartels S. Frequency of genetic alterations differs in advanced breast cancer between metastatic sites. Genes, Chromosomes and Cancer. Wiley; 2023; 10.1002/gcc.23199
• The dynamics of HER2-low expression during breast cancer progression Cite
  Anderson S, Bartow BB, Siegal GP, Huang X, Wei S. The dynamics of HER2-low expression during breast cancer progression. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07020-z
• Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers Cite
  Bergeron A, Bertaut A, Beltjens F, Charon-Barra C, Amet A, Jankowski C, et al. Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers. British Journal of Cancer. Springer Science and Business Media LLC; 2023; 129:122-134 10.1038/s41416-023-02287-x
• Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia Cite
  Ferrer M, Mourikis N, Davidson EE, Kleeman SO, Zaccaria M, Habel J, et al. Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia. Cell Metabolism. Elsevier BV; 2023; 10.1016/j.cmet.2023.05.008
• Evolution of biological features of invasive lobular breast cancer: comparison between primary tumor and metastases Cite
  Aliaga PT, Sandoval J, Trapani D, Nicolò E, Zagami P, Giugliano F, et al. Evolution of biological features of invasive lobular breast cancer: comparison between primary tumor and metastases. European Journal of Cancer. Elsevier BV; 2023; 10.1016/j.ejca.2023.02.028
• Abstract P3-05-08: Prevalence and prognosis of ER-loss in advanced invasive lobular carcinoma Cite
  Hensing WL, Xiu J, Korn WM, Graff SL, Kang I, Torres ETR, et al. Abstract P3-05-08: Prevalence and prognosis of ER-loss in advanced invasive lobular carcinoma. Cancer Research. American Association for Cancer Research (AACR); 2023; 83:P3-05-08-P3-05-08 10.1158/1538-7445.sabcs22-p3-05-08
• Characteristics of Patients With Metastatic Breast Cancer Who Survived more than 10 Years Cite
  KIKUCHI M, FUJII T, HONDA C, TANABE K, NAKAZAWA Y, OGINO M, et al. Characteristics of Patients With Metastatic Breast Cancer Who Survived more than 10 Years. Anticancer Research. Anticancer Research USA Inc.; 2022; 43:217-221 10.21873/anticanres.16152
• Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes – an observational cohort study in Sweden Cite
  Lindman H, Wiklund F, Andersen KK. Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes – an observational cohort study in Sweden. BMC Cancer. Springer Science and Business Media LLC; 2022; 22 10.1186/s12885-022-10098-1
• Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis Cite
  Rothé F, Venet D, Peeters D, Rouas G, Rediti M, Smeets D, et al. Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis. npj Breast Cancer. Springer Science and Business Media LLC; 2022; 8 10.1038/s41523-022-00445-7
• Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer Cite
  Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Therapeutic Advances in Medical Oncology. SAGE Publications; 2018; 10:175883591879332 10.1177/1758835918793326
• Modified Radical Mastectomy in De Novo Stage IV Inflammatory Breast Cancer Cite
  Chen JC, Li Y, Fisher JL, Bhattacharyya O, Tsung A, Bazan JG, et al. Modified Radical Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2022; 10.1245/s10434-022-11975-6
• Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer Cite
  Blancas I, Olier C, Conde V, Bayo JL, Herrero C, Zarcos-Pedrinaci I, et al. Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer. Scientific Reports. Springer Science and Business Media LLC; 2021; 11 10.1038/s41598-021-83622-1
• Should We Completely Exclude Locoregional Therapy for the Primary Tumor from Our Clinical Practice in De Novo Metastatic Breast Cancer? Cite
  Kus T, Aktas G. Should We Completely Exclude Locoregional Therapy for the Primary Tumor from Our Clinical Practice in De Novo Metastatic Breast Cancer?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2022; 10.1245/s10434-022-11979-2
• Standard of Care in Hormone Receptor–Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools? Cite
  D'Amico P, Cristofanilli M. Standard of Care in Hormone Receptor–Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools?. JCO Oncology Practice. American Society of Clinical Oncology (ASCO); 2022; 18:331-334 10.1200/op.21.00707
• Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study Cite
  Valachis A, Carlqvist P, Ma Y, Szilcz M, Freilich J, Vertuani S, et al. Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study. British Journal of Cancer. Springer Science and Business Media LLC; 2022; 10.1038/s41416-022-01845-z
• Metastasis patterns and prognosis in young breast cancer patients: a SEER database analysis Cite
  zhang w, Liu J, Zhang X, Yang C, Cao M, Zhang S, et al. Metastasis patterns and prognosis in young breast cancer patients: a SEER database analysis. Research Square Platform LLC; 2022; 10.21203/rs.3.rs-1434952/v1
• Impact of time to distant recurrence on breast cancer-specific mortality in hormone receptor-positive breast cancer Cite
  Calip GS, Nabulsi NA, Hubbard C, Asfaw AA, Lee I, Zhou J, et al. Impact of time to distant recurrence on breast cancer-specific mortality in hormone receptor-positive breast cancer. Cancer Causes & Control. Springer Science and Business Media LLC; 2022; 10.1007/s10552-022-01561-2
• Mortality After Late Breast Cancer Recurrence in Denmark Cite
  Pedersen RN, Mellemkjær L, Ejlertsen B, Nørgaard M, Cronin-Fenton DP. Mortality After Late Breast Cancer Recurrence in Denmark. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 10.1200/jco.21.02062
• The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry Cite
  Meegdes M, Ibragimova KIE, Lobbezoo DJA, Vriens IJH, Kooreman LFS, Erdkamp FLG, et al. The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-021-06472-5
• PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway Cite
  Zhou J, Imani S, Shasaltaneh MD, Liu S, Lu T, Fu J. PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway. Molecular Biology Reports. Springer Science and Business Media LLC; 2021; 10.1007/s11033-021-06990-x
• Efficacy of Resveratrol Against Advanced Breast Cancer-Derived Organoids: A comparison with that of Clinically Relevant Drugs Cite
  Ye H, Gao H, Li H, Nie J, Li T, Lu M, et al. Efficacy of Resveratrol Against Advanced Breast Cancer-Derived Organoids: A comparison with that of Clinically Relevant Drugs. Research Square Platform LLC; 2021; 10.21203/rs.3.rs-970702/v1
• Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database Cite
  Annonay M, Gauquelin L, Geiss R, Ung M, Cristol-Dalstein L, Mouret-Reynier M, et al. Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database. The Breast. Elsevier BV; 2021; 60:138-146 10.1016/j.breast.2021.09.011
• The Real-world Outcomes of Patients With Advanced Invasive Lobular Carcinoma of the Breast Compared With Invasive Ductal Carcinoma: A Review at a Single Institution Cite
  WATANABE J, NAKAMOTO S, SUGINO T. The Real-world Outcomes of Patients With Advanced Invasive Lobular Carcinoma of the Breast Compared With Invasive Ductal Carcinoma: A Review at a Single Institution. Anticancer Research. Anticancer Research USA Inc.; 2021; 41:4619-4627 10.21873/anticanres.15275
• Mediterranean Diet Food Components as Possible Adjuvant Therapies to Counteract Breast and Prostate Cancer Progression to Bone Metastasis Cite
  Maroni P, Bendinelli P, Fulgenzi A, Ferraretto A. Mediterranean Diet Food Components as Possible Adjuvant Therapies to Counteract Breast and Prostate Cancer Progression to Bone Metastasis. Biomolecules. MDPI AG; 2021; 11:1336 10.3390/biom11091336
• 1018Long-term risk of distant metastasis and post-metastasis survival for breast cancer: health record linkage study Cite
  Lord S, Daniels B, Kiely B, O'Connell D, Pearson S, Beith J, et al. 1018Long-term risk of distant metastasis and post-metastasis survival for breast cancer: health record linkage study. International Journal of Epidemiology. Oxford University Press (OUP); 2021; 50 10.1093/ije/dyab168.400
• Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study Cite
  Koh S, Ohsumi S, Takahashi M, Fukuma E, Jung KH, Ishida T, et al. Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study. Breast Cancer. Springer Science and Business Media LLC; 2021; 10.1007/s12282-021-01283-4
• Atorvastatin facilitates chemotherapy effects in metastatic triple-negative breast cancer Cite
  Marti JLG, Beckwitt CH, Clark AM, Wells A. Atorvastatin facilitates chemotherapy effects in metastatic triple-negative breast cancer. British Journal of Cancer. Springer Science and Business Media LLC; 2021; 10.1038/s41416-021-01529-0
• The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy Cite
  Vrieling C, Assele SY, Moser L, Sauvé N, Litière S, Fourquet A, et al. The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy. European Journal of Cancer. Elsevier BV; 2021; 155:28-37 10.1016/j.ejca.2021.06.018
• Prognostic significance of molecular subtype, metastatic site and primary tumor surgery for survival in primary metastatic breast cancer Cite
  Li Y, Wang S, Yang W, Liu H. Prognostic significance of molecular subtype, metastatic site and primary tumor surgery for survival in primary metastatic breast cancer. Medicine. Ovid Technologies (Wolters Kluwer Health); 2021; 100:e26619 10.1097/md.0000000000026619
• Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer Cite
  Watanabe T, Oba T, Tanimoto K, Shibata T, Kamijo S, Ito K. Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer. PLOS ONE. Public Library of Science (PLoS); 2021; 16:e0252822 10.1371/journal.pone.0252822
• HER2 receptor conversion is a strong survival predictor in patients with breast cancer brain metastases Cite
  Michel A, Oppong MD, Rauschenbach L, Pierscianek D, Dinger TF, Schmidt T, et al. HER2 receptor conversion is a strong survival predictor in patients with breast cancer brain metastases. World Neurosurgery. Elsevier BV; 2021; 10.1016/j.wneu.2021.05.096
• Network pharmacology-based evaluation of natural compounds with paclitaxel for the treatment of metastatic breast cancer Cite
  Rathaur P, Soni MN, Gelat B, Rawal R, Pandya HA, Johar K. Network pharmacology-based evaluation of natural compounds with paclitaxel for the treatment of metastatic breast cancer. Toxicology and Applied Pharmacology. Elsevier BV; 2021;:115576 10.1016/j.taap.2021.115576
• Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study Cite
  Zeppellini A, Galimberti S, Leone BE, Pacifico C, Riva F, Cicchiello F, et al. Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study. BMC Cancer. Springer Science and Business Media LLC; 2021; 21 10.1186/s12885-021-07960-z
• Tamoxifen suppresses brain metastasis of estrogen receptor-deficient breast cancer by skewing microglia polarization and enhancing their immune functions Cite
  Wu S, Sharma S, Wu K, Tyagi A, Zhao D, Deshpande RP, et al. Tamoxifen suppresses brain metastasis of estrogen receptor-deficient breast cancer by skewing microglia polarization and enhancing their immune functions. Breast Cancer Research. Springer Science and Business Media LLC; 2021; 23 10.1186/s13058-021-01412-z
• Abstract PS14-25: Outcomes of metastatic male breast cancer Cite
  Dogan I, Khanmammadov N, Aydıner A, Saip P. Abstract PS14-25: Outcomes of metastatic male breast cancer. Poster Session Abstracts. American Association for Cancer Research; 2021; 10.1158/1538-7445.sabcs20-ps14-25
• Abstract PS5-16: Impact of drug-drug interaction on palbociclib serum levels: Interest of therapeutic drug monitoring Cite
  Leenhardt F, Gracia M, Perrin C, Muracciole-Bich C, Marion B, Roques C, et al. Abstract PS5-16: Impact of drug-drug interaction on palbociclib serum levels: Interest of therapeutic drug monitoring. Poster Session Abstracts. American Association for Cancer Research; 2021; 10.1158/1538-7445.sabcs20-ps5-16
• Impact of body mass index on overall survival in patients with metastatic breast cancer Cite
  Saleh K, Carton M, Dieras V, Heudel P, Brain E, D’Hondt V, et al. Impact of body mass index on overall survival in patients with metastatic breast cancer. The Breast. Elsevier BV; 2021; 55:16-24 10.1016/j.breast.2020.11.014
• The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer Cite
  Partain N, Postlewait LM, Teshome M, Rosso K, Hall C, Song J, et al. The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2021; 10.1245/s10434-020-09392-8
• Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial Cite
  Leone JP, Cole BF, Regan MM, Thürlimann B, Coates AS, Rabaglio M, et al. Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial. Cancer. Wiley; 2020; 10.1002/cncr.33318
• Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study Cite
  Li X, Zhang X, Liu J, Shen Y. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study. BMC Cancer. Springer Science and Business Media LLC; 2020; 20 10.1186/s12885-020-07593-8
• Five-year relative survival by stage of breast and colon cancers in Italy Cite
  Mangone L, Mancuso P, Bisceglia I, Braghiroli B, Ferrari F, Vicentini M, et al. Five-year relative survival by stage of breast and colon cancers in Italy. Tumori Journal. SAGE Publications; 2020;:030089162096456 10.1177/0300891620964565
• Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer Cite
  Van Raemdonck E, Floris G, Berteloot P, Laenen A, Vergote I, Wildiers H, et al. Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05935-5
• Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer Cite
  Walter V, Fischer C, Deutsch TM, Ersing C, Nees J, Schütz F, et al. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 183:137-144 10.1007/s10549-020-05746-8
• Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT Cite
  Ulaner GA, Carrasquillo JA, Riedl CC, Yeh R, Hatzoglou V, Ross DS, et al. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT. Radiology. Radiological Society of North America (RSNA); 2020; 296:370-378 10.1148/radiol.2020192828
• A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer Cite
  Wang Z, Wang H, Ding X, Chen X, Shen K. A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer. Therapeutic Advances in Medical Oncology. SAGE Publications; 2020; 12:175883592093267 10.1177/1758835920932674
• Abstract C042: Cultivating the gut microbiome by eating walnuts to slow cancer cachexia weight loss Cite
  Chang H. Abstract C042: Cultivating the gut microbiome by eating walnuts to slow cancer cachexia weight loss. Poster Presentations - Proffered Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7755.disp18-c042
• Tumor shedding and metastatic progression after tumor excision in patient-derived orthotopic xenograft models of triple-negative breast cancer Cite
  Razmara AM, Sollier E, Kisirkoi GN, Baker SW, Bellon MB, McMillan A, et al. Tumor shedding and metastatic progression after tumor excision in patient-derived orthotopic xenograft models of triple-negative breast cancer. Clinical & Experimental Metastasis. Springer Science and Business Media LLC; 2020; 37:413-424 10.1007/s10585-020-10033-3
• Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016 Cite
  Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E, et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016. European Journal of Cancer. Elsevier BV; 2020; 129:60-70 10.1016/j.ejca.2020.01.016
• Abstract P6-15-05: Demographics and survival in metastatic inflammatory breast cancer. SEER data analysis Cite
  Anusim N, Ionescu F, Khoury J, Konde A, Jaiyesimi I. Abstract P6-15-05: Demographics and survival in metastatic inflammatory breast cancer. SEER data analysis. Poster Session Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7445.sabcs19-p6-15-05
• Abstract P5-08-25: Body mass index and liver metastasis in women with invasive breast carcinoma Cite
  Barron CR, Planas-Silva M, Hicks DG, Turner BM. Abstract P5-08-25: Body mass index and liver metastasis in women with invasive breast carcinoma. Poster Session Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7445.sabcs19-p5-08-25
• CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality Cite
  Curigliano G, Loibl S. CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality. The Lancet Oncology. Elsevier BV; 2020; 21:191-192 10.1016/s1470-2045(19)30808-3
• Breast Cancer With Brain Metastases: Perspective From a Long-Term Survivor Cite
  Kofron CP, Chapman A. Breast Cancer With Brain Metastases: Perspective From a Long-Term Survivor. Integrative Cancer Therapies. SAGE Publications; 2020; 19:153473541989001 10.1177/1534735419890017
• Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study Cite
  Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, et al. Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study. Breast Cancer. Springer Science and Business Media LLC; 2019; 27:389-398 10.1007/s12282-019-01029-3
• Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer Cite
  van Uden DJP, van Maaren MC, Strobbe LJA, Bult P, van der Hoeven JJ, Siesling S, et al. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer. Breast Cancer Research. Springer Science and Business Media LLC; 2019; 21 10.1186/s13058-019-1201-5
• Role of Curcumin in reducing toxicity and adverse effects in locally advanced and metastatic breast cancer patients Cite
  Goyal S, Beniwal SK, Kumar H, Kumar D, Das B. Role of Curcumin in reducing toxicity and adverse effects in locally advanced and metastatic breast cancer patients. Annals of Oncology. Elsevier BV; 2019; 30:vi126-vi127 10.1093/annonc/mdz343.041
• Long-Term Survival and Cure in Distant Metastatic Breast Cancer Cite
  Güth U, Elfgen C, Montagna G, Schmid S. Long-Term Survival and Cure in Distant Metastatic Breast Cancer. Oncology. S. Karger AG; 2019; 97:82-93 10.1159/000500298
• Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer Cite
  Ogiya R, Sagara Y, Niikura N, Freedman RA. Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2019; 19:200-207.e1 10.1016/j.clbc.2019.01.005
• Role of rebiopsy in metastatic breast cancer at progression Cite
  Sharma M, Gogia A, Deo SS, Mathur S. Role of rebiopsy in metastatic breast cancer at progression. Current Problems in Cancer. Elsevier BV; 2019; 43:438-442 10.1016/j.currproblcancer.2018.12.001
• Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial Cite
  Nanni O, Amadori D, De Censi A, Rocca A, Freschi A, Bologna A, et al. Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 174:433-442 10.1007/s10549-018-05070-2
• Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990–2011 Cite
  Malmgren J, Hurlbert M, Atwood M, Kaplan HG. Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990–2011. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 174:505-514 10.1007/s10549-018-05090-y
• Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies Cite
  Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, et al. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies. Nature Genetics. Springer Science and Business Media LLC; 2018; 51:207-216 10.1038/s41588-018-0287-5
• Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database Cite
  Chang E, Mougalian SS, Adelson KB, Young MR, Yu JB. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 173:209-216 10.1007/s10549-018-4968-7
• Long‐Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2‐Targeted Therapy Cite
  Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, et al. Long‐Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2‐Targeted Therapy. The Oncologist. Wiley; 2018; 24:313-318 10.1634/theoncologist.2018-0213
• Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort Cite
  Gobbini E, Ezzalfani M, Dieras V, Bachelot T, Brain E, Debled M, et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. European Journal of Cancer. Elsevier BV; 2018; 96:17-24 10.1016/j.ejca.2018.03.015
• Development of CNS metastases and survival in patients with inflammatory breast cancer Cite
  Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, et al. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. Wiley; 2018; 124:2299-2305 10.1002/cncr.31336
• Factors associated with improved outcomes for metastatic inflammatory breast cancer patients Cite
  Weiss A, Menen RS, Lin HY, Shen Y, Rosso KJ, Shaitelman S, et al. Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 169:615-623 10.1007/s10549-018-4715-0
• De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype Cite
  Press DJ, Miller ME, Liederbach E, Yao K, Huo D. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype. Clinical & Experimental Metastasis. Springer Science and Business Media LLC; 2017; 34:457-465 10.1007/s10585-017-9871-9
• Methylation patterns in serum DNA for early identification of disseminated breast cancer Cite
  Widschwendter M, Evans I, Jones A, Ghazali S, Reisel D, Ryan A, et al. Methylation patterns in serum DNA for early identification of disseminated breast cancer. Genome Medicine. Springer Science and Business Media LLC; 2017; 9 10.1186/s13073-017-0499-9
• Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer Cite
  Martel S, Poletto E, Ferreira AR, Lambertini M, Sottotetti F, Bertolini I, et al. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer. The Breast. Elsevier BV; 2018; 37:142-147 10.1016/j.breast.2017.11.004
• Prognostic outcomes in advanced breast cancer: the metastasis-free interval is important Cite
  Shen T, Gao C, Zhang K, Siegal GP, Wei S. Prognostic outcomes in advanced breast cancer: the metastasis-free interval is important. Human Pathology. Elsevier BV; 2017; 70:70-76 10.1016/j.humpath.2017.10.002
• Thirty-Year Trends of Survival and Time-Varying Effects of Prognostic Factors in Patients With Metastatic Breast Cancer—A Single Institution Experience Cite
  Rogoz B, Houzé de l'Aulnoit A, Duhamel A, Houzé de l'Aulnoit D. Thirty-Year Trends of Survival and Time-Varying Effects of Prognostic Factors in Patients With Metastatic Breast Cancer—A Single Institution Experience. Clinical Breast Cancer. Elsevier BV; 2018; 18:246-253 10.1016/j.clbc.2017.08.012
• A Young Female Athlete With Acute Low Back Pain Caused by Stage IV Breast Cancer Cite
  Kahn EA. A Young Female Athlete With Acute Low Back Pain Caused by Stage IV Breast Cancer. Journal of Chiropractic Medicine. Elsevier BV; 2017; 16:230-235 10.1016/j.jcm.2017.06.002
• Treatment Outcomes and Prognostic Factors in Male Patients With Stage IV Breast Cancer: A Population-based Study Cite
  Chen W, Huang Y, Lewis GD, Szeja SS, Hatch SS, Farach A, et al. Treatment Outcomes and Prognostic Factors in Male Patients With Stage IV Breast Cancer: A Population-based Study. Clinical Breast Cancer. Elsevier BV; 2018; 18:e97-e105 10.1016/j.clbc.2017.07.005
• Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes Cite
  Montagna E, Pirola S, Maisonneuve P, De Roberto G, Cancello G, Palazzo A, et al. Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes. Clinical Breast Cancer. Elsevier BV; 2018; 18:e401-e405 10.1016/j.clbc.2017.07.003
• Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study Cite
  Spera G, Fresco R, Fung H, Dyck J, Pituskin E, Paterson I, et al. Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study. Annals of Oncology. Elsevier BV; 2017; 28:1836-1841 10.1093/annonc/mdx264
• Metastatic Breast Cancer Cells Enter Into Dormant State and Express Cancer Stem Cells Phenotype Under Chronic Hypoxia Cite
  Carcereri de Prati A, Butturini E, Rigo A, Oppici E, Rossin M, Boriero D, et al. Metastatic Breast Cancer Cells Enter Into Dormant State and Express Cancer Stem Cells Phenotype Under Chronic Hypoxia. Journal of Cellular Biochemistry. Wiley; 2017; 118:3237-3248 10.1002/jcb.25972
• Abstract P6-09-30: Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab Cite
  Blanchette P, Desautels D, Pond G, Bartlett J, Nofech-Mozes S, Yaffe M, et al. Abstract P6-09-30: Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p6-09-30
• Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer Cite
  Inoue M, Nakagomi H, Nakada H, Furuya K, Ikegame K, Watanabe H, et al. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer. Breast Cancer. Springer Science and Business Media LLC; 2017; 24:667-672 10.1007/s12282-017-0753-4
• Impact of Primary Tumor Surgery in Stage IV Male Breast Cancer Cite
  Muzaffar M, Kachare S, Vohra N. Impact of Primary Tumor Surgery in Stage IV Male Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2017; 17:e143-e149 10.1016/j.clbc.2016.11.001
• Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial Cite
  Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet. Elsevier BV; 2016; 388:2997-3005 10.1016/s0140-6736(16)32389-3
• More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials Cite
  Vasista A, Stockler M, West T, Wilcken N, Kiely B. More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials. The Breast. Elsevier BV; 2017; 31:99-104 10.1016/j.breast.2016.10.007
• Site of metastasis and breast cancer mortality: a Danish nationwide registry-based cohort study Cite
  Ording AG, Heide-Jørgensen U, Christiansen CF, Nørgaard M, Acquavella J, Sørensen HT. Site of metastasis and breast cancer mortality: a Danish nationwide registry-based cohort study. Clinical & Experimental Metastasis. Springer Science and Business Media LLC; 2016; 34:93-101 10.1007/s10585-016-9824-8
• Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology) Cite
  Kaplan MA, Arslan UY, Işıkdogan A, Dane F, Oksuzoglu B, Inanc M, et al. Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology). Breast Care. S. Karger AG; 2016; 11:248-252 10.1159/000448186
• Effective Hormone Therapy Reduces the Efficacy of Subsequent Chemotherapy in Hormone-Receptor-Positive Metastatic Breast Cancer Cite
  Mori R. Effective Hormone Therapy Reduces the Efficacy of Subsequent Chemotherapy in Hormone-Receptor-Positive Metastatic Breast Cancer. Chemotherapy: Open Access. OMICS Publishing Group; 2016; 05 10.4172/2167-7700.1000210
• Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer Cite
  Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, et al. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 159:367-374 10.1007/s10549-016-3933-6
• Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis Cite
  Di Meglio A, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, et al. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 157:587-596 10.1007/s10549-016-3845-5
• Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer Cite
  Parkinson B, Viney R, Haas M, Goodall S, Srasuebkul P, Pearson S. Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer. PharmacoEconomics. Springer Science and Business Media LLC; 2016; 34:1039-1050 10.1007/s40273-016-0411-2
• Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer Cite
  Love RR, Hossain SM, Hussain MM, Mostafa MG, Laudico AV, Siguan SSS, et al. Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer. European Journal of Cancer. Elsevier BV; 2016; 60:107-116 10.1016/j.ejca.2016.03.011
• Effects of Dexamethasone and Placebo on Symptom Clusters in Advanced Cancer Patients: A Preliminary Report Cite
  Yennurajalingam S, Williams JL, Chisholm G, Bruera E. Effects of Dexamethasone and Placebo on Symptom Clusters in Advanced Cancer Patients: A Preliminary Report. The Oncologist. Wiley; 2016; 21:384-390 10.1634/theoncologist.2014-0260
• The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC) Cite
  Lee JY, Lim SH, Lee M, Kim HS, Ahn JS, Im Y, et al. The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC). PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0149432 10.1371/journal.pone.0149432
• Randomized trial of a physical activity intervention in women with metastatic breast cancer Cite
  Ligibel JA, Giobbie-Hurder A, Shockro L, Campbell N, Partridge AH, Tolaney SM, et al. Randomized trial of a physical activity intervention in women with metastatic breast cancer. Cancer. Wiley; 2016; 122:1169-1177 10.1002/cncr.29899
• Clinical predictors of long-term survival in HER2-positive metastatic breast cancer Cite
  Murthy P, Kidwell KM, Schott AF, Merajver SD, Griggs JJ, Smerage JD, et al. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:589-595 10.1007/s10549-016-3705-3
• Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes Cite
  Thomson AH, McGrane J, Mathew J, Palmer J, Hilton DA, Purvis G, et al. Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes. British Journal of Cancer. Springer Science and Business Media LLC; 2016; 114:793-800 10.1038/bjc.2016.34
• A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer Cite
  Kashiwaba M, Ito Y, Takao S, Doihara H, Rai Y, Kanatani K, et al. A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. Japanese Journal of Clinical Oncology. Oxford University Press (OUP); 2016; 46:407-414 10.1093/jjco/hyw013
• Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence Cite
  Brothers JM, Kidwell KM, Brown RKJ, Henry NL. Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:395-403 10.1007/s10549-016-3687-1
• Bone marrow micrometastases in early breast cancer–30-year outcome Cite
  Mansi J, Morden J, Bliss JM, Neville M, Coombes RC. Bone marrow micrometastases in early breast cancer–30-year outcome. British Journal of Cancer. Springer Science and Business Media LLC; 2016; 114:243-247 10.1038/bjc.2015.447
• A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition Cite
  Zucchini G, Armstrong A, Wardley A, Wilson G, Misra V, Seif M, et al. A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition. European Journal of Cancer. Elsevier BV; 2015; 51:2725-2731 10.1016/j.ejca.2015.08.028
• The association between diabetes and breast cancer stage at diagnosis: a population-based study Cite
  Lipscombe LL, Fischer HD, Austin PC, Fu L, Jaakkimainen RL, Ginsburg O, et al. The association between diabetes and breast cancer stage at diagnosis: a population-based study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 150:613-620 10.1007/s10549-015-3323-5
• Pattern of metastasis and outcome in patients with breast cancer Cite
  Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G, et al. Pattern of metastasis and outcome in patients with breast cancer. Clinical & Experimental Metastasis. Springer Science and Business Media LLC; 2015; 32:125-133 10.1007/s10585-015-9697-2
• A case of long term survival with skeletal only metastatic breast cancer Cite
  Kuechle JB, McGrath BE, Khoury T, Mindell ER. A case of long term survival with skeletal only metastatic breast cancer. International Journal of Surgery Case Reports. Elsevier BV; 2014; 6:280-284 10.1016/j.ijscr.2014.12.017
• Inflammatory Breast Cancer Management in the National Comprehensive Cancer Network: The Disease, Recurrence Pattern, and Outcome Cite
  Matro JM, Li T, Cristofanilli M, Hughes ME, Ottesen RA, Weeks JC, et al. Inflammatory Breast Cancer Management in the National Comprehensive Cancer Network: The Disease, Recurrence Pattern, and Outcome. Clinical Breast Cancer. Elsevier BV; 2015; 15:1-7 10.1016/j.clbc.2014.05.005
• Primary relapse site pattern in women with triple-negative breast cancer Cite
  Beca F, Santos R, Vieira D, Zeferino L, Dufloth R, Schmitt F. Primary relapse site pattern in women with triple-negative breast cancer. Pathology - Research and Practice. Elsevier BV; 2014; 210:571-575 10.1016/j.prp.2014.05.011
• Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient Cite
  Hoefnagel L, van der Groep P, van de Vijver M, Boers J, Wesseling P, Wesseling J, et al. Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient. Annals of Oncology. Elsevier BV; 2013; 24:3017-3023 10.1093/annonc/mdt390
• Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Cite
  Babayan A, Hannemann J, Spötter J, Müller V, Pantel K, Joosse SA. Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e75038 10.1371/journal.pone.0075038
• Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse Cite
  Jain S, Cohen J, Ward M, Kornhauser N, Chuang E, Cigler T, et al. Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. Annals of Oncology. Elsevier BV; 2013; 24:1491-1498 10.1093/annonc/mds654
• Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer Cite
  Pedersen AC, Sørensen PD, Jacobsen EH, Madsen JS, Brandslund I. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer. Clinical Chemistry and Laboratory Medicine. Walter de Gruyter GmbH; 2013; 51 10.1515/cclm-2012-0488
• Distant metastasis in triple-negative breast cancer Cite
  TSENG LM, HSU NC, CHEN SC, LU YS, LIN CH, CHANG DY, et al. Distant metastasis in triple-negative breast cancer. Neoplasma. AEPress, s.r.o.; 2013; 60:290-294 10.4149/neo_2013_038
• Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer Cite
  Aurilio G, Monfardini L, Rizzo S, Sciandivasci A, Preda L, Bagnardi V, et al. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Acta Oncologica. Informa UK Limited; 2013; 52:1649-1656 10.3109/0284186x.2012.754990
• Targeting insulin inhibition as a metabolic therapy in advanced cancer: A pilot safety and feasibility dietary trial in 10 patients Cite
  Fine EJ, Segal-Isaacson C, Feinman RD, Herszkopf S, Romano MC, Tomuta N, et al. Targeting insulin inhibition as a metabolic therapy in advanced cancer: A pilot safety and feasibility dietary trial in 10 patients. Nutrition. Elsevier BV; 2012; 28:1028-1035 10.1016/j.nut.2012.05.001
• Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology) Cite
  Kaplan MA, Isikdogan A, Koca D, Kucukoner M, Gumussoy O, Yildiz R, et al. Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology). Oncology. S. Karger AG; 2012; 83:141-150 10.1159/000338782
• Surgery for widely disseminated breast cancer: prolonged control by excision of metastases Cite
  Rees GJ, Britton DC, Malcolm GP, Rees M. Surgery for widely disseminated breast cancer: prolonged control by excision of metastases. JRSM Short Reports. SAGE Publications; 2012; 3:1-4 10.1258/shorts.2012.011162
• Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs) Cite
  Artac M, Bozcuk H, Kıyıcı A, Eren OO, Boruban MC, Ozdogan M. Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs). Breast Cancer. Springer Science and Business Media LLC; 2011; 20:174-180 10.1007/s12282-011-0322-1
• mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®) Cite
  Vázquez-Martín A, Oliveras-Ferraros C, del Barco S, Martín-Castillo B, Menéndez JA. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®). Clinical and Translational Oncology. Springer Science and Business Media LLC; 2009; 11:455-459 10.1007/s12094-009-0384-0
• Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer Cite
  Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, et al. Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:587-592 10.1200/jco.2010.33.5232
• Prognostic role of CA15.3 in 7942 patients with operable breast cancer Cite
  Sandri MT, Salvatici M, Botteri E, Passerini R, Zorzino L, Rotmensz N, et al. Prognostic role of CA15.3 in 7942 patients with operable breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 132:317-326 10.1007/s10549-011-1863-x
• Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression Cite
  Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:2601-2608 10.1200/jco.2011.37.2482
• Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study Cite
  Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, et al. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Research. Springer Science and Business Media LLC; 2011; 13 10.1186/bcr2944
• Significance of CA 27.29 (MUC 1 glycoprotein) levels in patients with breast cancer Cite
  Ghai V, Harvey HA, Abbi KK, Barochia A, Bhardwaj C, Demers LM. Significance of CA 27.29 (MUC 1 glycoprotein) levels in patients with breast cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2009; 27:e11579-e11579 10.1200/jco.2009.27.15_suppl.e11579
• The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors Cite
  Stuart-Harris R, Shadbolt B, Palmqvist C, Chaudri Ross H. The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors. The Breast. Elsevier BV; 2009; 18:351-355 10.1016/j.breast.2009.09.002
• Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial Cite
  Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le Floch O. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. British Journal of Cancer. Springer Science and Business Media LLC; 2009; 101:1978-1985 10.1038/sj.bjc.6605441